Resveratrol regulates microglia M1/M2 polarization via PGC-1α in conditions of neuroinflammatory injury

Brain, Behavior, and Immunity

Volumn 64, Issue , 2017, Pages 162-172

  Yang, Xiaodong ^a   Xu, Shaoqing ^a   Qian, Yiwei ^a   Xiao, Qin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Microglia polarization; Neuroinflammation; PGC; Resveratrol

Indexed keywords

ARGINASE 1; CD16 ANTIGEN; CD86 ANTIGEN; CHITINASE; CHITINASE 3 LIKE PROTEIN 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; STAT3 PROTEIN; STAT6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PPARGC1A PROTEIN, MOUSE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MICROGLIA ACTIVATION; MICROGLIA POLARIZATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; ANIMAL; CELL POLARITY; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL POLARITY; ENCEPHALITIS; HUMANS; MICE; MICROGLIA; NEUROPROTECTIVE AGENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; SIGNAL TRANSDUCTION; STILBENES;

EID: 85014744877     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2017.03.003     Document Type: Article

References (50)

1. Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group, Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 9 (2013), 714–723.
2. Baune, B.T., Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?. Curr. Opin. Psychiatry 28 (2015), 148–154.
3. Becker, C., Jick, S.S., Meier, C.R., NSAID use and risk of Parkinson disease: a population-based case-control study. Eur. J. Neurol. 18 (2011), 1336–1342.
4. Benkhart, E.M., Siedlar, M., Wedel, A., Werner, T., Ziegler-Heitbrock, H.W., Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J. Immunol. 165 (2000), 1612–1617.
5. Benveniste, E.N., Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. (Berl) 75 (1997), 165–173.
6. Burger, D., Molnarfi, N., Weber, M.S., Brandt, K.J., Benkhoucha, M., Gruaz, L., Chofflon, M., Zamvil, S.S., Lalive, P.H., Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 4355–4359.
7. Camara, M.L., Corrigan, F., Jaehne, E.J., Jawahar, M.C., Anscomb, H., Baune, B.T., Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology 40 (2015), 502–512.
8. Cantó, C., Auwerx, J., AMP-activated protein kinase and its downstream transcriptional pathways. Cell. Mol. Life Sci. 67 (2010), 3407–3423.
9. Cianciulli, A., Dragone, T., Calvello, R., Porro, C., Trotta, T., Lofrumento, D.D., Panaro, M.A., IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. Int. Immunopharmacol. 24 (2015), 369–376.
10. Colton, C.A., Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 4 (2009), 399–418.
11. Freedman, M.S., Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 76 (2011), S26–S34.
12. Fu, W., Zhuang, W., Zhou, S., Wang, X., Plant-derived neuroprotective agents in Parkinson's disease. Am. J. Transl. Res. 7 (2015), 1189–1202.
13. Handschin, C., Choi, C.S., Chin, S., Kim, S., Kawamori, D., Kurpad, A.J., Neubauer, N., Hu, J., Mootha, V.K., Kim, Y.B., Kulkarni, R.N., Shulman, G.I., Spiegelman, B.M., Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. J. Clin. Invest. 117 (2007), 3463–3474.
14. Handschin, C., Spiegelman, B.M., The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 454 (2008), 463–469.
15. Henry, C.J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M.T., Sheridan, J.F., Godbout, J.P., Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflamm sickness behavior, and anhedonia. J. Neuroinflammation, 5, 2008, 15.
16. Hou, X., Xu, S., Maitland-Toolan, K.A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T.J., Cohen, R.A., Zang, M., SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283 (2008), 20015–20026.
17. Hu, X., Li, P., Guo, Y., Wang, H., Leak, R.K., Chen, S., Gao, Y., Chen, J., Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43 (2012), 3063–3070.
18. Jha, M.K., Lee, W.H., Suk, K., Functional polarization of neuroglia: implications in neuroinflammation and neurological disorders. Biochem. Pharmacol. 2016:103 (2016), 1–16.
19. Joseph, B., Venero, J.L., A brief overview of multitalented microglia. Methods Mol. Biol. 1041 (2013), 3–8.
20. Katsouri, L., Blondrath, K., Sastre, M., Peroxisome proliferator-activated receptor-γ cofactors in neurodegeneration. IUBMB Life 64 (2012), 958–964.
21. Kieseier, B.C., The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 25 (2011), 491–502.
22. Kim, H.J., Park, K.G., Yoo, E.K., Kim, Y.H., Kim, Y.N., Kim, H.S., Kim, H.T., Park, J.Y., Lee, K.U., Jang, W.G., Kim, J.G., Kim, B.W., Lee, I.K., Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells. Antioxid. Redox Signal. 9 (2007), 301–307.
23. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., Auwerx, J., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006), 1109–1122.
24. Lofrumento, D.D., Nicolardi, G., Cianciulli, A., De Nuccio, F., La Pesa, V., Carofiglio, V., Dragone, T., Calvello, R., Panaro, M.A., Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun. 20 (2014), 249–260.
25. Maier, E., Duschl, A., Horejs-Hoeck, J., STAT6-dependent and -independent mechanisms in Th2 polarization. Eur. J. Immunol. 42 (2012), 2827–2833.
26. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004), 677–686.
27. Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000 Prime Rep., 6, 2014, 13.
28. Matsukawa, A., Takeda, K., Kudo, S., Maeda, T., Kagayama, M., Akira, S., Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J. Immunol. 171 (2003), 6198–6205.
29. Mikita, T., Campbell, D., Wu, P., Williamson, K., Schindler, U., Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol. Cell. Biol. 16 (1996), 5811–5820.
30. Moehle, M.S., West, A.B., M1 and M2 immune activation in Parkinson's Disease: foe and ally. Neuroscience 302 (2015), 59–73.
31. Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (2008), 958–969.
32. Mou, C., Liu, B., Wang, M., Jiang, M., Han, T., PGC-1-related coactivator (PRC) is an important regulator of microglia M2 polarization. J. Mol. Neurosci. 55 (2015), 69–75.
33. Nimmagadda, V.K., Bever, C.T., Vattikunta, N.R., Talat, S., Ahmad, V., Nagalla, N.K., Trisler, D., Judge, S.I., Royal, W., Chandrasekaran, K., Russell, J.W., Makar, T.K., Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. J. Immunol. 190 (2013), 4595–4607.
34. Niraula, A., Sheridan, J.F., Godbout, J.P., Microglia priming with aging and stress. Neuropsychopharmacology 42 (2017), 318–333.
35. Pauleau, A.L., Rutschman, R., Lang, R., Pernis, A., Watowich, S.S., Murray, P.J., Enhancer-mediated control of macrophage-specific arginase I expression. J. Immunol. 172 (2004), 7565–7573.
36. Perry, V.H., Nicoll, J.A., Holmes, C., Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6 (2010), 193–201.
37. Pervaiz, S., Holme, A.L., Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal. 11 (2009), 2851–2897.
38. Porro, C., Cianciulli, A., Calvello, R., Panaro, M.A., Reviewing the role of resveratrol as a natural modulator of microglial activities. Curr. Pharm. Des. 21 (2015), 5277–5291.
39. Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.S., Knapp, D.J., Crews, F.T., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55 (2007), 453–462.
40. Renaud, J., Bournival, J., Zottig, X., Martinoli, M.G., Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: effect on p53 and GRP75 localization. Neurotox. Res. 25 (2014), 110–123.
41. Scarpulla, R.C., Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev. 88 (2008), 611–638.
42. Song, J., Cheon, S.Y., Jung, W., Lee, W.T., Lee, J.E., Resveratrol induces the expression of interleukin-10 and brain-derived neurotrophic factor in BV2 microglia under hypoxia. Int. J. Mol. Sci. 15 (2014), 15512–15529.
43. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., Simon, D.K., Bachoo, R., Spiegelman, B.M., Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127 (2006), 397–408.
44. Tao, Y., Li, L., Jiang, B., Feng, Z., Yang, L., Tang, J., Chen, Q., Zhang, J., Tan, Q., Feng, H., Chen, Z., Zhu, G., Cannabinoid receptor-2 stimulation suppresses neuroinflammation by regulating microglial M1/M2 polarization through the cAMP/PKA pathway in an experimental GMH rat model. Brain Behav. Immun. 58 (2016), 118–129.
45. Tsunemi, T., La Spada, A.R., PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog. Neurobiol. 97 (2012), 142–151.
46. Vats, D., Mukundan, L., Odegaard, J.I., Zhang, L., Smith, K.L., Morel, C.R., Wagner, R.A., Greaves, D.R., Murray, P.J., Chawla, A., Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 4 (2006), 13–24.
47. Wang, Q., Liu, Y., Zhou, J., Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl. Neurodegener., 4, 2015, 19.
48. Xu, L., He, D., Bai, Y., Microglia-mediated inflammation and neurodegenerative disease. Mol. Neurobiol. 53 (2016), 6709–6715.
49. Xu, Y., Xu, Y., Wang, Y., Wang, Y., He, L., Jiang, Z., Huang, Z., Liao, H., Li, J., Saavedra, J.M., Zhang, L., Pang, T., Telmisartan prevention of LPS-induced microglia activation involves M2 microglia polarization via CaMKKβ-dependent AMPK activation. Brain Behav. Immun. 50 (2015), 298–313.
50. Yang, Y.J., Hu, L., Xia, Y.P., Jiang, C.Y., Miao, C., Yang, C.Q., Yuan, M., Wang, L., Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. J. Neuroinflammation, 13, 2016, 84.